» Articles » PMID: 35133487

Quantitative Analysis of Branching Neovascular Networks in Polypoidal Choroidal Vasculopathy by Optical Coherence Tomography Angiography After Photodynamic Therapy and Anti-vascular Endothelial Growth Factor Combination Therapy

Overview
Specialty Ophthalmology
Date 2022 Feb 8
PMID 35133487
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To study serial changes in branching neovascular networks (BNN) by using optical coherence tomography angiography (OCTA) in patients with polypoidal choroidal vasculopathy (PCV) who underwent combined photodynamic therapy (PDT) and anti-vascular endothelial growth factor (anti-VEGF) therapy.

Methods: In this retrospective study of 30 PCV patients who underwent combined therapy, OCTA images obtained at baseline and 1, 3, and 6 months after treatment were collected. The vessel area, vessel percentage area, average vessel length, and presence of polypoidal lesions on OCTA images as well as best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT) were recorded at each time point.

Results: The BNN- and polypoidal lesion-detection rates on baseline OCTA images were 100% and 71%, respectively. The vessel area decreased during the first 3 months, and increased 6 months post-treatment, showing significant differences from baseline (p = 0.031). The vessel percentage area also reduced 1 and 3 months post-treatment (p = 0.025) and increased 6 months post-treatment. Continuous polypoidal lesion regression was observed from 1 to 3 and 6 months post-treatment (p = 0.031, p = 0.004, p = 0.002, respectively, in comparison with baseline). Patients with a decreasing vessel area over 6 months showed greater choroidal thickness than those with increasing vessel area (p = 0.004).

Conclusions: The BNN showed initial regression but were enlarged at 6 months after therapy. Patients showing continuous BNN regression showed a thicker choroid at baseline. This difference should be considered during treatment for PCV, and OCTA could be used for follow-up evaluations of PCV patients.

Citing Articles

Recent Advances in Imaging Polypoidal Choroidal Vasculopathy with Swept-Source Optical Coherence Tomography Angiography.

Gu X, Zhao X, Zhao Q, Wang Y, Chen Y Diagnostics (Basel). 2023; 13(14).

PMID: 37510200 PMC: 10377931. DOI: 10.3390/diagnostics13142458.

References
1.
Imamura Y, Engelbert M, Iida T, Freund K, Yannuzzi L . Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010; 55(6):501-15. DOI: 10.1016/j.survophthal.2010.03.004. View

2.
Gemmy Cheung C, Lai T, Teo K, Ruamviboonsuk P, Chen S, Kim J . Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2020; 128(3):443-452. DOI: 10.1016/j.ophtha.2020.08.006. View

3.
Palkar A, Khetan V . Polypoidal choroidal vasculopathy: An update on current management and review of literature. Taiwan J Ophthalmol. 2019; 9(2):72-92. PMC: 6557071. DOI: 10.4103/tjo.tjo_35_18. View

4.
Spaide R, Yannuzzi L, Slakter J, Sorenson J, Orlach D . Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995; 15(2):100-10. DOI: 10.1097/00006982-199515020-00003. View

5.
Chen L, Cheng C, Yeung L, Yang C, Chen S . Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan. J Formos Med Assoc. 2019; 119(2):569-576. DOI: 10.1016/j.jfma.2019.04.012. View